Navigation Links
ThromboGenics Begins Preclinical Development of Anti-VPAC Antibody for Thrombocytopenia
Date:11/13/2007

LEUVEN, Belgium, November 14 /PRNewswire/ --

- Key Research Findings Published in the Leading Medical Journal `Blood' Validate Drug Target

ThromboGenics NV (Euronext Brussels: THR), a biotechnology company focused on vascular disease, announces today that it will progress with the development of its novel anti-VPAC(1) antibody for the treatment of thrombocytopenia, including chemotherapy-induced thrombocytopenia.

Thrombocytopenia, which is the reduced number of platelets in blood, is a common severe side effect of chemotherapy and increases the risk of bleeding and severity of haemorrhage, therefore causing the delay or even discontinuation of treatment in cancer patients. There is a high medical need to find a therapeutic that could reduce thrombocytopenia by accelerating platelet production. Blood transfusion, the current standard of care for this condition, offers only a temporary solution for these patients and is associated with significant cost and risk.

Researchers at the University of Leuven and ThromboGenics have developed a novel therapeutic approach, showing that the inhibition of VPAC could stimulate the production of platelets. ThromboGenics has now identified and selected a lead antibody against VPAC to enter preclinical development. VPAC is a receptor present at the surface of bone marrow cells called megakaryocytes, which, when mature, produce platelets. Research published yesterday in Blood describes how the inhibition of VPAC could promote megakaryocyte differentiation. Blood is the official journal of the American Society of Hematology (ASH).

Prof. Desire Collen, CEO and Chairman of ThromboGenics, commented: "Thrombocytopenia is a severe complication of cancer patients receiving chemotherapy, and for which there is little therapeutic alternative. I am very pleased to advance our thrombocytopenia programme to preclinical development, which I hope will confirm the potential of our approach published in Blood. Thi
'/>"/>

SOURCE ThromboGenics NV
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. Provectus Pharmaceuticals, Inc. Begins Phase 2 Clinical Trial for Metastatic Melanoma
2. PA Department of Public Welfare Begins Outreach to Medical Assistance Consumers Following Burglary at State Office Building
3. China Shenghuo Pharmaceutical Holdings, Inc. Begins Full-Scale Launch of 12Ways(R) Chinese Herbal Skin Care Product Line
4. Most comprehensive study of mercury in dental fillings begins
5. Eye Safety Begins at Home
6. MetLife Foundation Begins New Phase of Award-Winning Parenting Skills Campaign in Collaboration with the Partnership for a Drug-Free America(R)
7. OmniGuide Begins European Commercialization
8. From Microscope to Stethoscope: the MUHCs distinguished public lecture series begins a second seaso
9. From microscope to stethoscope: The MUHCs public lecture series begins its 2nd season tomorrow
10. North Shore-LIJ Health System Begins Online Posting of Hospital Infection Rates, Other Performance Information
11. Healthy Weight Loss Begins With What You Permit to Enter Your Mind, More So Than Even Your Mouth!
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2009)WASHINGTON, Dec. 5 ,, What: Cuts for a Cause ,, Why: To make a difference in the fight against cancer and other terminal illnesses affecting children. All proceeds from each hair service given
(Date:12/5/2009)... , , SATURDAY, Dec. 5 (HealthDay News) -- ...d asthma can have bad reactions to certain holiday...ent sneezing and wheezing, according to the Americ...I). , Those who are allergic to live evergreens ma...oth live and artificial trees can trigger symptoms...
(Date:12/5/2009)The MAMA campaign is a collaborative effort by the National Association of Certified Professional Midwives (NACPM), Midwives Alliance of North America (MANA), Citizens for Midwifery (CfM), Internation
(Date:12/4/2009)NEW YORK, Dec. 4 Thousands of KPMG LLP employees came together in more than 90 offices nationwide today, to participate in a community service event which combines the audit, tax and advisory firm,s
(Date:12/4/2009)SCOTTSDALE, Ariz., Dec. 4 Healthcare Trust of America, Inc. ("HTA"), a self-managed, non-traded, real estate investment trust, announced the execution of a purchase and sale agreement to acquire a th
Breaking Medicine News(10 mins):Health News:Keep Asthma, Allergies at Bay for the Holidays 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 2Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 3Health News:AquaNatal Birth Center Gives Away a Waterbirth Package to Celebrate the Successful MAMA Campaign 4Health News:KPMG Employees Provide 'Holiday Bear Hugs' and Books in Firmwide Service Day for Children 2Health News:Healthcare Trust of America, Inc. Executes Agreement to Acquire a 92,500 Square Foot Medical Office Portfolio Located in Texas and Indiana 2
...identified particular genes that are most prone to... called DNA promoter hypermethylation. Hy...ch support normal cell development, to generate pr...anism and causes of hypermethylation, particularly...
...ion between an extreme form of sleep disorder, REM...mentia or parkinsonism. Patients with RBD...body dementia, Parkinsons disease or multiple syst... of researchers led by Bradley Boeve at Mayo Clini...
...husiasts and experts in the capital are strongly o... Reacting to recent reports of yet another appl...s here feel that the very idea of patenting knowle...nal. The entire issue of patenting is very corpora...
...verage for mental illness does not increase usage ...s who have children with mental illness, a Yale S...lth Services Research. Prior research has ...t professor in the Department of Epidemiology & Pu...
... dangers of the rugby scrum could be a key reason ...uffered by rugby players, says a researcher writi...s, although rare, are a major cause of permanently...by Union in partnership with the Accident Compensa...
...r quacks either. A team of researchers in Pennsylv... follicles . And they have successfully created n...nal Nature, they say hair growth can actually be e...hese follicles are produced by the embryo in the f...
Other Medicine News:Health News:Researchers Have Identified Cancer Promoter Genes 2Health News:Researchers Find Link Between Sleep Disorder and Dementia 2Health News:Yoga Enthusiasts Oppose Patenting Yoga Overseas 2Health News:Coverage for Childrens Mental Illness Reduces Out-of-Pocket Spending 2Health News:Innovative Education Scheme Sees Fewer Rugby Players Suffering Spinal Injuries 2Health News:It is Possible Reverse Hair Loss, US Scientists Say 2
(Date:12/3/2009)ACTON, Mass., Dec. 3 Allen Medical Systems, a subsidiary of Hill-Rom Holdings, Inc. (NYSE: HRC ), today announced the launch of its new Allen Amatech(TM) OEM (Original Equipment Manufacturer) busin
(Date:12/3/2009)MADISON, N.J., Dec. 3 A genetic variation that may indicate a patient,s risk of developing a potentially life-threatening blood disorder if exposed to certain pharmaceutical therapies or chemicals is
(Date:12/3/2009)DOYLESTOWN, Pa., Dec. 3 Ted Karkus, Chairman and CEO of The Quigley Corporation, (Nasdaq: QGLY ) www.quigleyco.com announced today that the Company has completed its evaluation of its opportunitie
Breaking Medicine Technology:Allen Medical Systems Announces the Launch of New Allen Amatech(TM) OEM Website 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 2Quest Diagnostics Reveals New Genetic Discoveries for Testing for Leukemia, Lymphoma and Blood Clotting at 51st ASH Meeting and Exposition 3Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 2Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution 3Your Surroundings Mirror Your Beliefs 50509 1Your Surroundings Mirror Your Beliefs 50509 2Your Surroundings Mirror Your Beliefs 50509 3Morphotek 28R 29 Inc Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and 12866 1Morphotek 28R 29 Inc Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and 12866 2Morphotek 28R 29 Inc Announces a Research Collaboration Agreement with Synageva BioPharma Corporation to Develop Potential Treatments for Cancer and 12866 3eCardio Receives Significant Investment in Private Funding from Sequoia Capital 50507 1eCardio Receives Significant Investment in Private Funding from Sequoia Capital 50507 2
...agnostics Histoplasma DxSelect is intended for qua...sulatum var. capsulatum in human serum. The test i... respiratory disease, as an aid in the presumptive...is test is not intended for self-testing, and this...
...unofluorescent antibody (IFA) test for the detecti...dies to St. Louis Encephalitis (SLE), Western Equi... (EEE), and California Encephalitis/La Crosse (CE)...s with fixed individual spots of SLE, WEE, EEE, an...
Epstein-Barr Nuclear Antigen (EBNA) ACIF (Anti-Complement Immunofluorescence)
CMF OL1000 Bone Growth Stimulators
Medicine Products: